Starpharma to present DEP® at Boston ADC summit (ASX Announcement)
Apr 27th, 2022
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.
Read More
Dr Jeff Davies appointed as non-executive director (ASX Announcement)
Feb 24th, 2022
Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.
Read More
Starpharma to present DEP® at US Drug Delivery Conference (ASX Announcement)
Oct 28th, 2021
Starpharma today announced that it has been invited to present at the 11th annual Partnership Opportunities in Drug Delivery (PODD) conference, which will take place virtually this year on 28‑29 October 2021.
Read More
US patent issued for DEP® cabazitaxel nanoparticle (ASX Announcement)
Sep 15th, 2021
Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP® cabazitaxel.
Read More